Daewoong Pharmaceutical opens Chinese laboratory

Published: 16-Dec-2014
Research & Development

Now established in Beijing and Shenyang


Korean drug company Daewoong Pharmaceutical has taken a step towards establishing a global network with its recently built Daewoong Pharmaceutical Liaoning laboratory in China becoming operational.

The newly built lab, located in the Benxi Economic Development Zone near Shenyang, will develop oral solution products and solid formulations for Chinese consumers. The lab is under Liaoning Baifeng, a Shenyang-based drug manufacturer acquired by the Korean company in August 2013.

Daewoong Pharmaceuticals now has a corporate body and offices in Beijing and factories and labs in Shenyang. With these establishments, the company plans to reach sales revenue of US$463.4m within China by 2020.

The drug lab adopts an open collaboration strategy that encourages collaboration with major institutions in the three Northeast Provinces in China, such as the local colleges of pharmacy, research centres and other pharmaceutical companies in drug technologies and research.

  • Companies:
  • Daewoong Pharmaceutical
See more

You may also like

Research & Development

AffyXell expands partnership with GenScript ProBio

Read more
As part of the strategic alliance, GenScript has committed to take an equity position in AffyXell at a future funding round

Trending Articles

  1. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  2. Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody Prima BioMed announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761
  3. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  4. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  5. Macomics unveils Anti-Pan-LILRB monoclonal antibody programme Data presented at AACR 2024 shows MACO-355 is highly potent in macrophage reprogramming under tumour-like immune suppressed conditions

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

AffyXell expands partnership with GenScript ProBio

As part of the strategic alliance, GenScript has committed to take an equity position in AffyXell at a future funding round
Ingredients

Affibody announces diabetes option exercise by Daewoong

Affibody will receive a license conversion fee and milestone payments as well as royalties. Further financial details were not disclosed.
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Ardena's nanomedicines facility marks expansion with first GMP approval

The EUR €20m expansion to the nanomedicines facility at Pivot Park has achieved operational status by the Dutch Healthcare Authority
Research & Development

Compact process thermostat for efficient temperature control in the laboratory

The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Subscribe now